Managing director of 1798, A Fingerpaint Company
Roshawn Blunt is a highly respected biotech consultant who has had extensive success cultivating industry partnerships, influencing stakeholders, and delivering positive results. She began her pharmaceutical career at Boston Consulting Group before transitioning out of consulting and into positions on the manufacturer and provider sides, such as her role as a health policy director in Washington, DC, at Amgen, followed by being the global director of health economics at Johnson & Johnson. She also worked in healthcare as the head of strategy, marketing, and communications for Long Beach Memorial Medical Center and Miller Children’s Hospital. Roshawn returned to consulting as the managing director at the Aequitas Group. She founded 1798, where her leadership has helped multiple companies achieve first-in-industry market access milestones. 1798 was acquired by Fingerpaint in 2020. Roshawn earned a bachelor’s degree in international and public affairs at Princeton University and an MBA with a concentration in marketing and biotechnology at Northwestern University Kellogg School of Management.